Bayer's anticoagulant rivaroxaban non-inferior to standard therapy in Phase III DVT trial
This article was originally published in Scrip
Executive Summary
Bayer/Johnson & Johnson's anticoagulant Xarelto (rivaroxaban) has been shown to be non-inferior to standard therapy with Sanofi-Aventis's Lovenox (enoxaparin) and warfarin in a Phase III trial testing it as treatment for deep vein thrombosis (DVT).